SMS Pharmaceuticals has recently informed exchanges that the company successfully completed its second inspection by the United States Food and Drug Administration (USFDA) at its Central Laboratory Analytical Services in Gagillapur, Hyderabad.
The inspection, held from June 23 to June 25, 2025, concluded with zero Form 483 observations, reflecting the company’s strong focus on quality and compliance.
This Central Lab is an independent analytical testing facility, and the clean inspection outcome reaffirms SMS Pharma’s commitment to CGMP and GLP standards across all its units. The company continues to maintain world-class quality practices, ensuring trust and reliability in every aspect of its operations.
In the meantime, SMS Pharmaceuticals shares closed today at ₹239.00, after opening at ₹234.25. The stock touched an intraday high of ₹239.90 and a low of ₹234.25 during the session. The company’s 52-week high stands at ₹398.00, while the 52-week low is ₹176.05.
